title: Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
abstract: Cholera vaccine candidate Peru-15 was derived from a Vibrio cholerae O1 El Tor Inaba strain by deleting the cholera toxin genetic element, introducing the gene encoding cholera toxin B subunit into recA, and screening for nonmotility. In a controlled study, Peru-15 (2 x 10(8) cfu) was administered to 11 volunteers. No vaccinee developed diarrhea, and 10 of 11 had > 4-fold rises in vibriocidal antibody titers. One month later, 5 vaccinees and 5 control volunteers were challenged with wild type V. cholerae O1. Four of 5 controls developed diarrhea (mean, 1.9 L). Two Peru-15 vaccinees developed diarrhea, 1 with < 0.3 L and 1 with approximately 1.0 L; this latter volunteer had not developed a significant vibriocidal immune response to vaccination. Peru-15 shows promise as a single-dose, oral cholera vaccine that is safe, immunogenic, and protective.
authors.affiliation: US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Kenner
authors.forename: T S
authors.initials: TS
authors.lastname: Coster
authors.forename: D N
authors.initials: DN
authors.lastname: Taylor
authors.forename: A F
authors.initials: AF
authors.lastname: Trofa
authors.forename: M
authors.initials: M
authors.lastname: Barrera-Oro
authors.forename: T
authors.initials: T
authors.lastname: Hyman
authors.forename: J M
authors.initials: JM
authors.lastname: Adams
authors.forename: D T
authors.initials: DT
authors.lastname: Beattie
authors.forename: K P
authors.initials: KP
authors.lastname: Killeen
authors.forename: D R
authors.initials: DR
authors.lastname: Spriggs
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D002771:Cholera / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000517:prevention & control; D006801:Humans; D012449:Safety; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic